Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
NCT07529925Phase 4Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of adalimumab in plaque psoriasis, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start May 2026; status: not yet recruiting.
02
Drugs
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07529925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529925.